Home › NDC Lookup › RxCUI directory › RxCUI 2105633

Larotrectinib 100 MG Oral Capsule — RxCUI 2105633

Name: Larotrectinib 100 MG Oral Capsule (RxCUI 2105633)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2105633 Semantic clinical drug · SCD ● Current RxNorm concept 7 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2105633

Official nameLarotrectinib 100 MG Oral Capsule

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known aslarotrectinib 100 MG (as 123 MG larotrectinib sulfate) oral capsule

FDA products mapped7

Package NDCs mapped7

Reported Medicaid activity (SDUD)38 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Larotrectinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Vitrakvi isn't tied to one specific cancer type — it targets a specific genetic change called an NTRK gene fusion that can show up in many different solid tumors, in both adults an...
What kind of cancer is Vitrakvi actually used for?
Good news — you can take Vitrakvi with or without food, whichever is more convenient or comfortable for you. A high-fat meal can slightly change how quickly the drug is absorbed, b...
Can I take Vitrakvi with food, or does it have to be on an empty stomach?

📖 Read our full Larotrectinib guide →

🕸️ Concept Web — How Larotrectinib 100 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Larotrectinib 100 MG Oral Capsule RxCUI 2105633 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Larotrectinib 2105628 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Vitrakvi 2105640 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Larotrectinib Oral Capsule 2105632 SCDF
- Larotrectinib Oral Product 2105630 SCDG
- Larotrectinib Pill 2105631 SCDG
- Larotrectinib Oral Capsule [Vitrakvi] 2105642 SBDF
- Vitrakvi Oral Product 2105643 SBDG
- Vitrakvi Pill 2105644 SBDG
- Oral Capsule 316965 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Larotrectinib 100 MG 2105629 SCDC
- Larotrectinib 100 MG Oral Capsule [Vitrakvi] 2105645 SBD
- Larotrectinib 100 MG [Vitrakvi] 2105641 SBDC

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Larotrectinib 100 MG SCDC · 2105629
Larotrectinib Oral Capsule SCDF · 2105632
Larotrectinib Oral Product SCDG · 2105630
Larotrectinib Pill SCDG · 2105631

Brand-Name Concepts

Larotrectinib 100 MG Oral Capsule [Vitrakvi] SBD · 2105645
Larotrectinib 100 MG [Vitrakvi] SBDC · 2105641
Larotrectinib Oral Capsule [Vitrakvi] SBDF · 2105642
Vitrakvi Oral Product SBDG · 2105643
Vitrakvi Pill SBDG · 2105644
Vitrakvi BN · 2105640

📦 FDA Products & Package NDCs

7 products · 7 package NDCs

7 package NDCs map to RxCUI 2105633 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
50419-0390-01	60 CAPSULE in 1 BOTTLE (50419-390-01)	VITRAKVI	Bayer HealthCare Pharmaceuticals Inc.	2019-07-26
50419-0391-01	60 CAPSULE in 1 BOTTLE (50419-391-01)	VITRAKVI	Bayer HealthCare Pharmaceuticals Inc.	2019-07-26
50419-0392-01	100 mL in 1 BOTTLE (50419-392-01)	VITRAKVI	Bayer HealthCare Pharmaceuticals Inc.	2019-07-26
50419-0393-03	2 BOTTLE in 1 CARTON (50419-393-03) / 50 mL in 1 BOTTLE (50...	VITRAKVI	Bayer HealthCare Pharmaceuticals Inc.	2022-12-06
71777-0390-01	60 CAPSULE in 1 BOTTLE (71777-390-01)	VITRAKVI	Loxo Oncology, Inc.	2018-11-26
71777-0391-01	60 CAPSULE in 1 BOTTLE (71777-391-01)	VITRAKVI	Loxo Oncology, Inc.	2018-11-26
71777-0392-01	100 mL in 1 BOTTLE (71777-392-01)	VITRAKVI	Loxo Oncology, Inc.	2018-11-26

Observed labelers: Bayer HealthCare Pharmaceuticals Inc. (4) · Loxo Oncology, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.